Compare Amgen, Inc. (AMGN) vs Crocs, Inc. (CROX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Crocs, Inc. — how do they compare? Amgen, Inc. trades at $363.49 (market cap $196.12B), while Crocs, Inc. trades at $133 (market cap $6.60B). The key difference: Amgen, Inc. is far larger — about 29.7× Crocs, Inc.'s market cap, and Amgen, Inc. pays a 2.77% dividend while Crocs, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | CROX | |
|---|---|---|
Market Cap | $196.12B | $6.60B |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $132.78 |
52-Week Low | $271.18 | $73.39 |
Enterprise Value | $241.41B | $8.19B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Crocs (CROX) trades at $132.78, up 4.44% with bullish technical signals and consistent earnings beats. The stock shows strong momentum above key support levels, though profitability metrics declined in 2025 with negative net income margins. Recent partnerships with LEGO and Disney are driving brand innovation and digital engagement.
Outlook remains mixed with analyst consensus favoring Buy (51%) but fundamental headwinds from margin pressure. Key risks include execution on international expansion and debt management. The stock trades near analyst target of $131.75 with upside to $150 if growth initiatives succeed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
